"Adalimumab is an effective therapy for patients with noninfectious uveitis, but is associated with more adverse effects than placebo, according to a recent phase 3 clinical trial (VISUAL I). These results were published in the September 8 issue o"...
Mitosol® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin in the past. 4.2 Pregnant women Mitosol® may cause fetal harm when administered to a pregnant woman. Mitomycin administered parenterally has been shown to be teratogenic in mice and rats when given at doses equivalent to the usual human intravenous dose. Mitosol® is contraindicated in women who are or may become pregnant during therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/21/2016
Additional Mitosol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.